Expert knowledge from The Pirbright Institute has helped to secure a £500,000 award from the Department for Environment, Food and Rural Affairs (DEFRA) to advance bovine respiratory syncytial virus (BRSV) vaccine research.
The Vaccine Group Limited (TVG) and the Animal and Plant Health Agency (APHA) have been awarded the funding in partnership with Innovate UK. It will be used to build on the outstanding success enjoyed by two TVG vaccine candidates in Innovate UK Smart-backed trials in calves run by APHA, the results of which were announced in November 2025.
TVG Chief Executive Officer Dr Jeremy Salt said: “We are delighted to continue working with APHA, and with Dr Geraldine Taylor at The Pirbright Institute, who is providing specialist input. The BRSV vaccines have enormous potential, and I am optimistic about their commercial prospects.”
Dr Geraldine Taylor, a specialist in BRSV at The Pirbright Institute, said: “I acted as a consultant for earlier studies, providing advice, the challenge virus, reagents and protocols for analysis of the immune response induced by the vaccine and analysis of BRSV replication in the calves after challenge.
“BRSV is the leading viral cause of respiratory illness in young calves in the UK. We hope our work towards a vaccine will relieve the substantial economic burden currently faced by both beef and dairy producers.”
BRSV is a highly contagious and economically damaging disease in cattle globally. The new study will determine the minimum vaccine dose needed to provide effective protection and assess whether this can be achieved following a single vaccination.
As part of the new project, specialist animal health and veterinary group Synergy Farm Health will study the incidence, treatment and associated antibiotic use of bovine respiratory disease in English cattle herds. The findings will help place the vaccine research in its practical farming context and inform future studies.
TVG has also reported strong results for a pig vaccine candidate to tackle Streptococcus suis, a zoonotic disease which can cause meningitis, sepsis and other symptoms in humans. The success of both trials shows TVG’s novel herpesvirus-based vaccine platform works against viral and bacterial diseases, and in different animal species.